IER3 (Immediate Early Response 3) antibodies are specialized immunological tools designed to detect and quantify the IER3 protein, a stress-inducible regulator involved in apoptosis, proliferation, and cellular stress responses . Also known as IEX-1, this protein is encoded by the IER3 gene (Entrez Gene ID: 8870) and is widely expressed across tissues, including the liver, pancreas, and hematopoietic systems . IER3 antibodies are critical for studying its role in cancer progression, autophagy, and signaling pathways such as ERK and AKT/mTOR .
The following table summarizes widely used IER3 antibodies, validated across platforms like Western blot (WB), immunohistochemistry (IHC), and flow cytometry (FC):
Hepatocellular Carcinoma (HCC): IER3 is upregulated in HCC tissues and correlates with poor prognosis (HR = 1.30, 95% CI 1.03–1.64) . Antibodies confirmed elevated IER3 expression via IHC and RNA-seq .
Acute Myeloid Leukemia (AML): High IER3 expression promotes autophagy and tumorigenesis by suppressing AKT/mTOR phosphorylation. Knockdown reduced LC3B-II levels, indicating autophagy inhibition .
IER3 regulates apoptosis in cardiomyocytes, with dysregulation linked to dilated cardiomyopathy (DCM). NF-κB signaling induces IER3 transcription, influencing apoptotic gene expression .
IER3 antibodies enable differentiation of HCC from non-HCC tissues (AUC = 0.65, 95% CI 0.61–0.69) .
Prognostic utility in AML: Higher IER3 mRNA levels predict shorter survival (p < 0.0001) .
In pancreatic cancer, IER3 confers resistance to gemcitabine by activating the NUPR1/RELB/IER3 survival pathway .
Targeting IER3-mediated autophagy could inhibit AML progression .